Essex Woodlands Management, Inc. purchased $21.2M worth of shares in EyePoint Pharmaceuticals, Inc. in June 2018

Jul 08, 2018
Insider Transactions
Background Information
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Essex Woodlands Health Ventures focuses on diversified healthcare investing. They invest in the pharmaceutical, biotechnology, medical device, services and information technology sectors. They tend to focus on early-stage investments, but may also make later-stage investments including mature venture, growth equity and PIPE investment opportunities.